Never Miss Important Company Updates Again

Get AI-powered summaries of SEC filings delivered to your inbox

Follow your favorite stocks and get email alerts when they release important updates. Completely free.

Covers 5,000+ public companies

Get started →

Sign up to stay up to date with the stocks you care about

Most recent public disclosures: AI-powered summaries of the latest corporate filings

1451

1

TRANSCONTINENTAL REALTY INVESTORS INC Transcontinental Realty Reports Decrease in Net Income and Revenue for Fiscal Year 2024

Via official filing (AI summary) | about 1 month ago | 0 comments

1452

1

Bakkt Holdings, Inc. Bakkt Holdings Reports $349M Revenue Surge and $103.4M Net Loss for 2024

Via official filing (AI summary) | about 1 month ago | 0 comments

1453

1

AMERICAN REALTY INVESTORS INC American Realty Investors Reports $14.7 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 month ago | 0 comments

1454

1

AlTi Global, Inc. AlTi Global Reports $174.3 Million Net Loss for 2024, Revenue Declines to $206.9 Million

Via official filing (AI summary) | about 1 month ago | 0 comments

1455

1

GYRE THERAPEUTICS, INC. Gyre Therapeutics Reports $17.9M Net Income for 2024, Improved Profitability Amid Revenue Decline

Via official filing (AI summary) | about 1 month ago | 0 comments

1456

1

AGENUS INC Agenus Inc. Reports $232.3 Million Net Loss for 2024, Decreased R&D Revenue

Via official filing (AI summary) | about 1 month ago | 0 comments

1457

1

Akoya Biosciences, Inc. Akoya Biosciences Reports $81.7M Revenue in 2024, Faces Net Loss of $55.4M

Via official filing (AI summary) | about 1 month ago | 0 comments

1458

1

OCULUS INC. Oculus Inc. Reports $327,360 Net Loss for Fiscal Year 2024, Seeks Additional Financing

Via official filing (AI summary) | about 1 month ago | 0 comments

1459

1

FIBROGEN INC Fibrogen Reports 37% Revenue Decline to $29.6 Million for 2024

Via official filing (AI summary) | about 1 month ago | 0 comments

1460

1

Sana Biotechnology, Inc. Sana Biotechnology Reports $266.76 Million Net Loss for 2024, Improved from Previous Year

Via official filing (AI summary) | about 1 month ago | 0 comments

1461

1

ATAI Life Sciences N.V. ATAI Life Sciences Reports $149.3 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 month ago | 0 comments

1462

1

SANGAMO THERAPEUTICS, INC Sangamo Therapeutics Reports $97.9 Million Net Loss and Decreased Revenues in 2024

Via official filing (AI summary) | about 1 month ago | 0 comments

1463

1

Metagenomi, Inc. Metagenomi Reports $78.1 Million Net Loss for 2024, Highlights IPO and R&D Progress

Via official filing (AI summary) | about 1 month ago | 0 comments

1464

1

CBAK Energy Technology, Inc. CBAK Energy Technology Reports $176.6M Revenue and $9.6M Net Income for Fiscal Year 2024

Via official filing (AI summary) | about 1 month ago | 0 comments

1465

1

FVCBankcorp, Inc. FVCBankcorp Reports Significant Increase in Net Income to $15.1 Million for Fiscal Year 2024

Via official filing (AI summary) | about 1 month ago | 0 comments

1466

1

Cannabist Co Holdings Inc. The Cannabist Company Reports $105.9 Million Net Loss for Fiscal Year 2024

Via official filing (AI summary) | about 1 month ago | 0 comments

1467

1

COGNITION THERAPEUTICS INC Cognition Therapeutics Reports $33.97 Million Net Loss for 2024, Concludes Phase 2 MAGNIFY Study

Via official filing (AI summary) | about 1 month ago | 0 comments

1468

1

MSC INCOME FUND, INC. MSC Income Fund Reports $56.5M Net Increase in Assets for 2024, NYSE Listing Planned

Via official filing (AI summary) | about 1 month ago | 0 comments

1469

1

ARS Pharmaceuticals, Inc. ARS Pharmaceuticals Reports $8M Net Income for 2024, Driven by Neffy Launch

Via official filing (AI summary) | about 1 month ago | 0 comments

1470

1

Avalo Therapeutics, Inc. Avalo Therapeutics Reports $35.1 Million Net Loss for 2024, Highlights AlmataBio Acquisition

Via official filing (AI summary) | about 1 month ago | 0 comments

1471

1

Invivyd, Inc. Invivyd Reports $169.9 Million Net Loss for 2024, Highlights PEMGARDA Sales

Via official filing (AI summary) | about 1 month ago | 0 comments

1472

1

Monte Rosa Therapeutics, Inc. Monte Rosa Therapeutics Reports $72.7 Million Net Loss for 2024, Highlights Collaboration Revenue Growth

Via official filing (AI summary) | about 1 month ago | 0 comments

1473

1

Neuraxis, INC Neuraxis Reports $8.2 Million Net Loss, Revenue Increases by 9.2% in Fiscal Year 2024

Via official filing (AI summary) | about 1 month ago | 0 comments

1474

1

22nd Century Group, Inc. 22nd Century Group Reports 24.3% Revenue Decline, Focuses on Reduced Nicotine Products

Via official filing (AI summary) | about 1 month ago | 0 comments

1475

1

ABEONA THERAPEUTICS INC. Abeona Therapeutics Reports $63.7 Million Net Loss and Nil Revenue for Fiscal Year 2024

Via official filing (AI summary) | about 1 month ago | 0 comments